摘要
目的探讨治疗前^(18)F-FDG PET/CT最大标准摄取值(maximum standardized uptake value,SUV_(max))等临床因素对惰性B细胞淋巴瘤(indolent B-cell nontlodgkin’s lymphoma,B-iNHL)的预后判断价值。方法收集2012-2017年本院收治的初诊且治疗前行PET/CT检查的98例B-iNHL患者的临床资料,分析治疗前SUV_(max)等临床因素与预后之间的关系。结果 98例B-iNHL患者中位SUV_(max)6. 8(1. 8～25. 4),其中滤泡性淋巴瘤(follicular lymphoma,FL) 43例,中位SUV_(max)7. 8(3. 6～20. 3),非FL55例,中位SUV_(max)5. 3(1. 8～25. 4),差异有统计学意义(P=0. 001)。依据SUV_(max)分为高SUV_(max)组(SUV_(max)> 7. 25) 39例(39. 8%);低SUV_(max)组(SUV_(max)≤7. 25) 59例(60. 2%)。单因素及多因素分析显示SUV_(max)> 7. 25是影响无进展生存(progression-free survival,PFS)及总生存(overall survival,OS)的独立预后危险因素(P <0. 05)。高SUV_(max)组3年PFS率为43. 8%,显著低于SUV_(max)组(85. 9%,P=0. 001;高SUV_(max)组) 3年OS率为79. 0%,显著低于低SUV_(max)组(98. 3%,P=0. 002)。高SUV_(max)组病死率23. 1%(9/39),低SUV_(max)组病死率1. 7%(1/59),差异有统计学意义(P=0. 001)。结论^(18)F-FDG PET/CT SUV_(max)是影响B-iNHL患者PFS及OS的独立预后危险因素,对B-iNHL患者预后判断具有一定参考价值。
Objective To investigate the value of the maximun standardized uptake value(SUVmax)in 18F-FDG PET-CT before treatment in predicting the survival outcomes of patients with indolent B-cell lymphoma(B-iNHL).Methods The clinical data were collected from 98 patients with B-iNHL diagnosed and treated in our hospital from January,2012 to December,2017.All the patients,including 43 with follicular lymphoma and 55 with nonfollicular lymphoma,underwent 18F-FDG PET-CT before treatment,and the correlation of SUVmaxwith the survival outcomes of the patients were analyzed.Results The median SUVmaxwas 6.8(range 1.8-25.4) in the overall 98 patients with B-iNHL.The median SUVmaxwas significantly higher in patients with follicular lymphoma than those with nonfollicular lymphoma [7.8(3.6-20.3) vs 5.3(1.8-25.4) ],P = 0.001).According to the level of SUVmax,the 98 patients were divided into high SUVmax(>7.25;n = 39) group and low SUVmax(≤7.25;n = 59) group,and univariate and multivariate analyses showed that a SUVmax>7.25 was an independent risk factor that affected progression-free survival(PFS) and overall survival(OS) of the patients(P< 0.05).Compared with those with low SUVmax before treatment,the patients with high SUVmaxhad a significantly lower 3-year estimated PFS rate(43.8% vs85.9%,P< 0.05) and 3-year estimated OS rate(79.0% vs 98.3%,P< 0.05).Nine patients in high SUVmaxgroup and 1 in low SUVmaxgroup died,showing a significant difference in the mortality rate between the two groups(9/39 vs 1/59,23.1% vs 1.7%,P = 0.001).Conclusion SUVmaxin 18F-FDG PET-CT is an independent risk factor affecting PFS and OS of the patients with B-iNHL and can be used as a predictor of the survival outcomes of the patients.
作者
万鑫
王书楠
国巍
唐杨
王兴彤
刘明锁
白鸥
WAN Xin;WANG Shunan;GUO Wei;TANG Yang;WANG Xingtong;LIU Mingsuo;BAI Ou(Department of Hematology,Cancer Center,First Hospital of Jilin University,Changchun,Jilin Province,130021,China)
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2019年第4期366-370,共5页
Journal of Third Military Medical University
基金
吉林省财政厅资助(2018SCZWSZX-031)~~
关键词
惰性淋巴瘤
В细胞
PET/CT
SUVMAX
indolent lymphoma,B cells
positron emission tomography/computed tomography
SUVmax
